Hormone replacement therapy in breast cancer patients and survivors

Current Women's Health Reports

Volumn 3, Issue 2, 2003, Pages 165-169

  Del Priore, Giuseppe ^a   Hatami, Mehrangiz ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; REVIEW; TREATMENT INDICATION; UNITED STATES; VASOMOTOR DISORDER; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; NEOPLASM; RISK FACTOR; SURVIVOR; TUMOR RECURRENCE;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; RISK FACTORS; SURVIVORS;

EID: 0037665965     PISSN: 15345874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Anonymous: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
2. Bush TL, Whiteman M, Flaws JA: Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001, 98:498-508.
3. Cheek J, Lacy J, Toth-Fejel S, et al.: The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 2002, 137: 1015-1021.
4. Del Priore G, Smith JR, Boyle DC, et al.: Uterine transplantation, abdominal trachelectomy, and other reproductive options for cancer patients. Ann NY Acad Sci 2001, 943:287-295.
5. Harris PF, Remington PL, Trentham-Dietz A, et al.: Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002, 23:501-509.
6. Mortimer JE: Hormone replacement therapy and beyond: the clinical challenge of menopausal symptoms in breast cancer survivors. Geriatrics 2002, 57:25-31.
7. Pritchard KI, Khan H, Levine M: Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. CMAJ 2002, 166:1017-1022.
8. Nelson HD, Humphrey LL, Nygren P, et al.: Postmenopausal hormone replacement therapy: scientific review. JAMA 2002, 288:872-881.
9. Lemay A: The relevance of the women's health initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can 2002, 24:711-715.
10. Mills PK, Beeson WL, Phillips RL, Fraser GE: Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer 1989, 64:591-597.
11. Dew J, Eden J, Beller E, et al.: A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998, 1:137-142.
12. Pansini F, Bacchi Modena AB, de Aloysio D, et al.: Sociodemographic and clinical factors associated with HRT use in women attending menopause clinics in Italy. Climacteric 2000, 3:241-247.
13. Tibolone: New preparation. Menopausal symptoms: oestrogen-progestrogen combinations are still the reference treatment. Prescrire Int 2002, 11:79-82.
14. Carpenter JS, Johnson D, Wagner L, Andrykowski M: Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 2002, 29:E16-E25.
15. Durna EM, Wren BG, Heller GZ, et al.: Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002, 177:347-351.
16. Dew JE, Wren BG, Eden JA: Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric 2002, 5:151-155.
17. Esteve J, Seradour B, Jacquemier J, Remontet L: Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography. J Med Screen 2002, 9:70-73.
18. O'Meara ES, Rossing MA, Daling JR, et al.: Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001, 93:754-762.
19. Natrajan PK, Gambrell RD Jr: Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 2002, 187:289-295.
20. Paridaens R, Paridaens R, Heuson JC, et al.: Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: preliminary results of a double-blind randomized study of the EORTC Breast Cancer Cooperative Group. J Steroid Biochem Mol Bio 1990, 37:1109-1113.
21. Kiang DT, Gay J, Goldman A, Kennedy BJ: A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 1985, 313:1241-1246.
22. Matelski H, Greene R, Huberman M, et al.: Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am J Clin Oncol 1985, 8:128-133.
23. Li R, Gilliland FD, Baumgartner K, Samet J: Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women. Cancer 2002, 95:960-968.
24. Kirsh V, Kreiger N: Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control 2002, 13:589-590.
25. Ratanawichitrasin A, Reansuwan W, Ratanawichitrasin S, et al.: Risk of breast cancer in post-menopausal women using hormone replacement therapy. J Med Assoc Thai 2002, 85:583-589.
26. Newcomb PA, Titus-Ernstoff L, Egan KM, et al.: Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:593-600.